SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Idera Pharmaceuticals, Inc. Reports Preclinical Mechanism of Action Data on IMO-8400, a Novel TLR Inhibitor for Autoimmune Diseases